Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Role of Naloxone in Opioid Overdose Fatality Prevention; Request for Comments; Public Workshop

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), in collaboration with the Office of the Assistant Secretary for Health, National Institutes of Drug Abuse and the Centers for Disease Control and Prevention, is announcing a scientific workshop to initiate a public discussion about the potential value of making naloxone more widely available outside of conventional medical settings to reduce the incidence of opioid overdose fatalities. Academia, government, industry experts and patient advocates will be assembled to discuss which populations are at-risk for opioid overdose and how public health groups are working together to curb the abuse of opioids. We will also seek to identify potential health concerns, social concerns, legal concerns, regulatory issues and future research needs related to making naloxone more widely available.


April 12, 2012


8:30 a.m. to 5:30 p.m.


10903 New Hampshire Avenue
Bldg. 31 Conference Center
Silver Spring, MD 20993

Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance.


Page Last Updated: 12/15/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English